Is the Broad Institute exploiting its nonprofit status to corner CRISPR business?

Print Friendly, PDF & Email

When a federal patent court ruled that the nonprofit Broad Institute of MIT and Harvard could legally license its version of the CRISPR-Cas9 genome-editing system, it opened the door to millions of dollars of revenue for the institute. It also contributed to the seismic shift occurring in science whereby tax-exempt research institutes established under an emerging model of “free market philanthropy” can amass money to further their research and protect their commercial interests.

The Broad Institute, a tax-exempt organization established by contributions totaling $1.4 billion by Eli Broad and Ted Stanley, is hardly the only one of these nonprofit models.

The tax-exempt Broad draws National Institutes of Health funding to subsidize dozens of basic research projects, many of them conducted with commercial partners. But it is the Broad’s handling of its own CRISPR business and partnerships that threaten to undermine its nonprofit mission.

These nonprofit-corporate partnerships raise questions about the extent to which taxpayers should subsidize tax-exempt biomedical research by nonprofits that retain the rights to license patents and appear willing to defend them in court.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: The Broad Institute is testing the limits of what ‘nonprofit’ means

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists